ACTICLATE Drug Patent Profile
✉ Email this page to a colleague
When do Acticlate patents expire, and what generic alternatives are available?
Acticlate is a drug marketed by Chartwell Rx and is included in two NDAs.
The generic ingredient in ACTICLATE is doxycycline hyclate. There are twenty-eight drug master file entries for this compound. Seventy-two suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Acticlate
A generic version of ACTICLATE was approved as doxycycline hyclate by CARIBE HOLDINGS on November 8th, 1982.
Summary for ACTICLATE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 55 |
Patent Applications: | 438 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ACTICLATE |
What excipients (inactive ingredients) are in ACTICLATE? | ACTICLATE excipients list |
DailyMed Link: | ACTICLATE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ACTICLATE
US Patents and Regulatory Information for ACTICLATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chartwell Rx | ACTICLATE | doxycycline hyclate | TABLET;ORAL | 205931-001 | Jul 25, 2014 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Chartwell Rx | ACTICLATE | doxycycline hyclate | TABLET;ORAL | 205931-002 | Jul 25, 2014 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Chartwell Rx | ACTICLATE CAP | doxycycline hyclate | CAPSULE;ORAL | 208253-001 | Apr 26, 2016 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |